1388651-30-6

Basic information

• Product Name: N-(3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl)-5-(difluoromethyl)pyrazine-2-carboxamide
• CAS NO: 1388651-30-6
• Molecular Weight: 437.445
• Mol File: 1388651-30-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: N-(3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl)-5-(difluoromethyl)pyrazine-2-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl)-5-(difluoromethyl)pyrazine-2-carboxamide(1388651-30-6)
• EPA Substance Registry System: N-(3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl)-5-(difluoromethyl)pyrazine-2-carboxamide(1388651-30-6)

Safety Data

• Hazardous Substances Data: 1388651-30-6(Hazardous Substances Data)

Usage

Description

N-(3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl)-5-(difluoromethyl)pyrazine-2-carboxamide is a complex organic molecule with a pyrazine-2-carboxamide core, featuring a fluorophenyl and difluoromethyl group, as well as an amino-methyl-furo-thiazinyl group. Its intricate structure suggests potential interactions with biological targets or receptors, indicating possible pharmacological properties or medicinal applications.

Uses

Used in Pharmaceutical Industry:
N-(3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl)-5-(difluoromethyl)pyrazine-2-carboxamide is used as a potential pharmaceutical compound for its possible interactions with biological targets or receptors, which may lead to the development of new drugs or therapies.
Used in Chemical Research:
In the field of chemical research, this compound serves as a subject for studying the effects of its unique structural features on its chemical and biological properties, potentially contributing to the advancement of organic chemistry and medicinal chemistry.

Upstream product

• 5521-55-1 2-methylpyrazin-5-carboxylic acid 
• 36070-80-1 5-chloropyrazinoic acid 
• 210037-58-4 5-bromopyrazine-2-carboxylic acid methyl ester 
• 1174321-06-2 5-(difluoromethyl)pyrazine-2-carboxylic acid 
• 1384462-08-1 (4aS,5R,7aS)-7a-(2-Fluorophenyl)-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-2-amine 

Relevant articles and documents

Synthesis of BACE1 Inhibitors E2609 / E2071 via Oxime-Olefin Cycloaddition following a Process Risk Mitigation Strategy

Process development of E2609 from the preclinical stage to the clinical stage following a process risk mitigation strategy is described here. Key features include a turbo Grignard reaction monitored by in-situ IR, [3 + 2] cycloaddition in water, chemoselective amide coupling via in-situ protection, and a Reformatsky/decarboxylation approach to install a difluoromethyl group. Toward safe and scalable manufacture of E2071, an analog of E2609, a flow-reaction process for trifluoromethylation of aldehydes is presented here.

FUSED AMINODIHYDROTHIAZINE DERIVATIVES

A compound represented by the general formula: or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C6-14 aryl group or the like, L is —NReCO— or the like (wherein Re is a hydrogen atom or the like), Ring B is a C6-14 aryl group or the like, X is a C1-3 alkylene group or the like, Y is a single bond or the like, Z is a C1-3 alkylene group or the like, R1 and R2 are each independently a hydrogen atom or the like, and R3, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, has an Aβ production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ and typified by Alzheimer-type dementia.